Individuals found to have a hereditary breast cancer syndrome should be managed appropriately, with an emphasis on screening considerably earlier than standard recommendations.
This information was originally presented at the NCCN 2019 Congress Series™: Breast Cancer with Updates from the 2018 San Antonio Breast Cancer Symposium (SABCS) held in Chicago, Illinois, on February 8, 2019.
This information was originally presented at the NCCN 2019 Congress Series™: Breast Cancer with Updates from the 2018 San Antonio Breast Cancer Symposium (SABCS) held in Chicago, Illinois, on February 8, 2019.
Clinicians who work with breast cancer survivors need to be informed about the prevalence of and risk factors for lymphedema, its negative impact, and current management recommendations so that all survivors with lymphedema receive optimal treatment.
Incorporating appropriate assays along with the traditional biomarkers in clinical decision-making still remains a challenge as all available tools have advantages and limitations that the clinicians should understand and explain to patients.
Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The treatment of breast cancer is rapidly evolving.
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer.
The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
Facebook
X
LinkedIn
Forward
